Original Article:

The Utility of Beta 2 Microglobulin (B2M) as an Initial Diagnostic Tool for Oral Squamous Cell Carcinoma (OSCC): Evidence from a Malaysian Scenario

Maithrea Suresh Narayanan¹, Nur Karyatee Kassim², Tang Liszen³, Baharuddin Abdullah⁴, Julia Omar⁵, Suhaily Mohd. Hairon⁶, Norhafiza Mat Lazim⁷

Abstract:

Background: The delay in diagnosis of oral squamous cell carcinoma (OSCC) is a factor in rendering the poor prognosis, and recent research has explored the use of serum tumour markers such Beta 2 Microglobulin (B2M), to aid early diagnosis. However, despite a high incidence of OSCC in Southeast Asia, no studies on the clinical use of B2M in the region were found.

Objectives: To determine if serum B2M level can serve as an initial diagnostic tool to indicate if a biopsy is warranted, and if so, to propose a local B2M serum reference value to identify OSSC patients.

Methodology: Twenty-one patients were seen at Hospital Universiti Sains Malaysia (HUSM) for a one-year period, between June 2016 and June 2017, and equal number of healthy controls participated in the study. Apart from patient history, venous blood of approximately 5ml volume was collected from each subject at the pre-treatment stage and analysed by an Abbot ARCHITECT c8000 analyser using the immunoturbidimetry method. The results were analysed using ROC analysis and the Mann Whitney test.

Results:

Serum B2M levels showed a statistically significant increase (p<0.001) in patients compared to controls. The test was shown to have 90.5% sensitivity and 90.5% specificity. It was found to be a sensitive and specific serum tumour marker at a cut off value of 1.57mg/l to differentiate cases from controls.

Conclusion: B2M is a sensitive and specific tumour marker to differentiate OSCC cases from controls. It is cost effective and minimally invasive, making it a potentially useful adjunct diagnostic tool in a high-risk patient pool.

Keywords: Oral Squamous Cell carcinoma; Beta 2 Microglobulin; serum marker

Introduction

Oral cancer is defined as a malignant neoplasm arising from oral cavity or oropharynx; and commonly involves sub-sites such as the anterior two-thirds of the tongue, tonsils, upper and lower alveolar ridge, buccal mucosa, and the hard palate¹. Oral cancer is the 6th most common cancer in the world but shows wide geographical variation, but a higher incidence has been noted in South and Southeast Asian countries such as India, Bangladesh, Taiwan, and Sri Lanka².

1. Maithrea Suresh Narayanan, Department of Otorhinolaryngology - Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
2. Nur Karyatee Kassim, School of Dental Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
3. Tang Liszen, Oral and Maxillofacial Surgery Unit, School of Dental Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
4. Baharuddin Abdullah, Department of Otorhinolaryngology - Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
5. Julia Omar, Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
6. Suhaily Mohd. Hairon, Department of Community Medicine, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
7. Norhafiza Mat Lazim, Department of Otorhinolaryngology - Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.

Correspondence to: Nur Karyatee Kassim, School of Dental Sciences, Universiti Sains Malaysia Health Campus, 16150 Kota Bharu, Kelantan, Malaysia. Email address: karyatee@usm.my
Squamous cell carcinoma constitutes about 90% of oral malignancies with tumours arising from minor salivary glands accounting for a further 5%.[1]

Local epidemiology data from the 2007 National Cancer Registry in Malaysia reported a total of 353 cases of oral cancer; it was ranked as the 21st most common cancer in the general population; the 17th most common among males and the 16th most common among females. Furthermore, only 35.4% of the 205 cases reported with staging were of stages I and II.[1] Oral squamous cell carcinoma (OSCC) is characterised by a high rate of metastasis, recurrence, and second malignancy; with a poor prognosis.[4,5] The 5-year survival rate for OSCC is approximately 50% and has remained so for the past several decades.[6]

This lack of improvement is attributed to the fact that a large number of cases are diagnosed at an advanced stage. The prognosis of patients with early treatment is much better, with 5-year survival rates as high as 80%.[7] Thus, early detection is vital.

OSCC is a multifactorial disease, and the risk factors include smoking, alcohol consumption, betel quid chewing, poor oral hygiene and diet and nutritional deficiencies, especially in vitamin A, C, E, iron, selenium, folate and phosphate. Other factors such as human papilloma virus (HPV) infection and premalignant conditions such as leukoplakia and erythroplakia have also shown to influence the pathogenesis Clinical oral examination (COE) is the gold standard for the initial detection of dysplastic or malignant oral lesions at an early stage, with confirmation by biopsy and histopathological examination (HPE). However, a recent systematic review concluded that the overall performance of COE as a diagnostic method for predicting dysplasia and OSCC has been poor.[8] HPE is a time-consuming process, requiring several days to fix, embed and stain the biopsy specimen.[9] The specimen can also be affected by artefacts resulting from crushing, incorrect fixation and freezing.[10] Furthermore, the biopsy process is invasive in nature and can pose technical difficulties to the clinician when lesions are extensive, as the most representative areas must be selected to avoid diagnostic errors.[11] As such, the proportion of OSCC cases diagnosed at an early and localised stage is still <50% within a 5-year period.[12,13] It has also been observed that a majority of patients failed to recognise the early signs and symptoms of OSCC.[14] Furthermore, 30-40% of patients with a negative nodal status at resection eventually die from metastatic disease.[15] Thus, it is clear that the current diagnostic methods on which treatment modality is based are of insufficient sensitivity. A non-invasive, cost-effective and rapid method for early diagnosis of OSCC is, therefore, a priority.

Tumour markers are substances found in blood, urine, or body tissues that can be elevated by the presence of one or more types of cancer. Recent research has explored the use of these markers to aid early diagnosis of carcinoma and they have been shown to have a wide range of potential applications, including screening, prognosis, and monitoring for recurrence or metastasis.[8] One such tumour marker is the Beta 2 Microglobulin (B2M) which was first described in 1968.[16] B2M is a low molecular weight protein on the beta-chain of the human leukocyte antigen (HLA). It occurs physiologically in small quantities in human urine, plasma, and cerebrospinal fluid. It exists in two main forms, free or non-covalently linked to HLA antigens. The free form, which is relevant as a biomarker, is found in serum, and consists of a single polypeptide chain with a single intrachain disulfide bridge with no carbohydrate content.[16,17]

According to a recent meta-analysis on the diagnostic accuracy of serum biomarkers for head and neck cancer, 15 biomarkers were reported as having excellent sensitivity and specificity but only B2M was reported as fulfilling the accuracy criteria twice.[18] The increased production of B2M by carcinoma cells compared to non-neoplastic cells may be due to increased cell synthesis, breakdown, or both.[19] B2M levels have been reported to be significantly increased in individuals exposed to carcinogens, having premalignant conditions, at different stages of oral cancer and histological differentiation, when compared with healthy controls.[20-22] However, it has been shown that serum B2M is a superior diagnostic tool when compared to B2M level in saliva for OSCC.[23] Upregulation of B2M expression in tumour tissue has been associated with OSCC progression, invasion and metastasis, while the suppression of B2M expression in in-vitro studies using small interfering RNA (siRNA) has been shown to decrease cell migration and invasion.[24,25]

This study had two inter-related objectives: to establish if serum B2M level can serve as an initial diagnostic tool to quickly determine if further investigation through biopsy is warranted for patients suspected of having OSCC. And if so, to propose a local reference serum B2M value that can be used...
to identify OSSC patients. A review of the literature showed no studies on the clinical use of a B2M cut off level specific to the local Southeast Asian population, despite a high incidence of the disease in the region. The level of B2M serum has several strengths. First, it is an inexpensive, less invasive technique that provides rapid results. Second, it avoids inter-observer variations associated with other simpler alternatives. Finally, raised B2M levels serve to increase the index of suspicion regarding the presence of OSSC, in the case of a negative biopsy.

Materials and methods

Case and control group selection

This study involved a total of 42 patients from a single centre, Hospital Universiti Sains Malaysia (HUSM), in Kelantan, Malaysia. Subjects were made up of two groups. The ‘case’ group was made up of OSSC patients seen at the Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) and Oral and Maxillofacial (OMF) Surgery clinics of HUSM, over a period of one year, between June 2016 and June 2017. A matching number of healthy individuals were also recruited to serve as the ‘control’ group. Eligible subjects for the case group were those with the clinically evident oral lesion, with HPE confirmation, and had not undergone any previous therapy/treatment for oral cancer and were willing to provide written consent. Non-eligible subjects were those who had an autoimmune disease, who were pregnant, or were being treated for an active infection, or had an underlying kidney/liver disease, or previous diagnosis of another malignancy, or were unwilling or unable to give written consent. A total of 21 out of 30 patients satisfied the eligibility criteria to form the case group. The control group was made up of 21 healthy subjects recruited from those accompanying patents to the ORL-HNS clinic, and through advertisements placed in the ORL-HNS clinic inviting voluntary participation as control subjects. Their health status was established after a physical examination and blood screening to rule out pre-existing medical conditions or pregnancy. Written informed consent was obtained from all subjects.

Sample characteristics

The ethnic composition of the case group correctly reflects the composition of the population of the study area with 95% being Malay, and about 5% being Chinese. The control group had a larger representation of the Chinese. There were no Indian subjects in our sample (Table 1)

Table 1: Demographic characteristics of OSCC and control group

| Variables | OSCC (n=21) | Control (n=21) |
|-----------|------------|----------------|
| Mean age (SD) | 60.62 (10.60) | 43.67 (8.09) |
| Gender: | | |
| Female | 8 (38.1) | 15 (71.4) |
| Male | 13 (61.9) | 6 (28.6) |
| Race: | | |
| Indian | 0 | 0 |
| Chinese | 1 (4.8) | 5 (23.5) |
| Malay | 20 (95.2) | 16 (76.2) |

*Percentages in parentheses

Both case and control groups were drawn from subjects aged between 18 to 80 years old, with the mean age among the case group being 60.6 years, with most of them within the 60-69 age range. The mean age among controls was lower (43.7 years). Males predominated in both case and control groups.

OSCC Assessment

Data regarding patient demographics, risk factors, histopathology and stage of disease were collected and recorded on a data collection sheet. All blood samples were collected according to a standard collection protocol. About 5mls of blood was collected in a test tube. The samples were centrifuged at 3000 rpm for 5 minutes after being clotted for 30 -60 minutes at room temperature. Aliquots of serum samples were stored at -80°C until analysis was performed. Samples were processed by an Abbot Architect c8000 analyser using the immunoturbidimetry method for the quantitative determination of B2M. The detection limit was 0.046 mg/L.

Statistical analyses

Statistical associations were analysed using SPSS software, version 23.0. A p-value of < 0.05 was taken to be statistically significant at a confidence level of 95%. All the numerical data were presented as medians (IQR) while categorical data were expressed as percentages (%). Analytical statistics were done using the Mann-Whitney test and Receiving Characteristic Operating Curve (ROC) analysis.

Ethical clearance: The study protocol was reviewed and approved by the Human Research Ethics Committee (HREC) of USM (Study protocol code USM/JEPeM 16030139.)

Results

The 21 subjects in the case group had HPE confirmed OSCC, with a staging CT done but no prior treatment.
The most common site of presentation of the primary tumour was the tongue (47.6%), followed by buccal mucosa (33.3%). Smoking was the highly prevalent risk factor for OSCC (71.4%) among the case group, as compared to betel quid chewing (23.8%). All the patients were in Stage IV of the disease, with moderately differentiated squamous cell carcinoma being the most common (52.4%) histopathological presentation (Table 2).

Table 2: Risk factors and site of the lesion according to histological differentiation of OSCC patients (n=21)

| Variables | Moderately differentiated (n=11) | Well differentiated (n=10) |
|-----------|---------------------------------|---------------------------|
| Mean age (SD) | 62.55 (9.61) | 58.50 (10.91) |
| Smokingɑ | Non-smoker | 3 (14.3) | 2 (9.5) |
| | Ex-smoker | 4 (19.0) | 3 (14.3) |
| | 0-20 sticks/day | 3 (14.3) | 4 (19.0) |
| | 21-40 sticks/day | 1 (4.8) | 1 (4.8) |
| Betel quid chewingɑ | No | 9 (42.9) | 7 (33.3) |
| | Yes | 2 (9.5) | 3 (14.3) |
| Alcohol intake | 0 | 0 |
| Site of malignancyɑ | Lip | 0 (0) | 1 (4.8) |
| | Tonsil | 2 (9.5) | 1 (4.8) |
| | Buccal | 4 (19.0) | 3 (14.3) |
| | Tongue | 5 (23.8) | 5 (23.8) |

ɑ Percentages in parentheses

The median serum B2M level in the control group was 1.37 (0.16) mg/l and 2.56 (1.04) mg/l in the case group. This higher serum B2M level in the case group, as compared to the control group, was statistically significant (p<0.001) (Table 3).

Table 3: Comparison of serum B2M levels between the groups using the by Mann-Whitney test

| Groups | B2M level (mg/l) | Median (IQR) | z-statistic | p-value |
|--------|-----------------|--------------|-------------|---------|
| OSCC Cases | 2.56 (1.04) | -5.26 | <0.001 |
| Control group | 1.37 (0.16) |  |

Among the 10 cases with well differentiated OSCC, the median serum B2M level was 2.44 (1.51) mg/l, while in 11 cases of moderately differentiated OSCC, the level was 2.67 (0.78) mg/l. Increased serum B2M level was thus seen to be correlated with the degree of histological differentiation, although the difference was not statistically significant (p =0.833) (Table 4).

Table 4: Comparison of serum B2M level according to histological grade of differentiation by the Mann-Whitney Test

| Histopathological grade | B2M level (mg/l) | Median (IQR) | z-statistic | p-value |
|-------------------------|-----------------|--------------|-------------|---------|
| Moderately differentiated | 2.67 (0.78) | -0.21 | 0.833 |
| Well differentiated | 2.44 (1.51) |  |

In ROC analysis, a B2M value of 1.586 mg/l was taken as a cut-off value for differentiating cases from controls. The recorded area under the ROC curve was 0.97. Thus, our study shows a 90.5% sensitivity and 90.5% specificity (Table 5).

Table 5: Diagnostic test accuracy measurements of serum B2M from ROC analysis

| Serum B2M | OSCC patients | Total |
|-----------|---------------|-------|
| | Cases | Controls | |
| Positive | 19 (TP)ɑ | 2 (FP)β | 21 |
| | 2 (FN)β | 19 (TN)β | 21 |
| Total | 21 | 21 | 42 |

ɑ True Positive  β True Negative  γ False Positive  δ False negative

Sensitivity = 90.5%  Specificity = 90.5%  Positive Predictive Value = 90.5%  Negative Predictive Value = 90.5%  Positive Likelihood Ratio (LR positive) = 9.53  Negative Likelihood Ratio (LR negative) = 0.10  Diagnostic Odds Ratio = 95.3  Youden Index = 0.81

Median serum B2M level was 1.85 (1.67) mg/l for patients with a nodal status of N0 (4 cases), and 2.67 (0.79) mg/l in patients with positive nodes (17 cases). However, this was not statistically significant (p = 0.244) (Table 6).

Table 6: Comparison of serum B2M level according to nodal status, by the Mann-Whitney Test

| Nodal status | B2M level (mg/l) | Median (IQR) | z-statistic | p-value |
|--------------|-----------------|--------------|-------------|---------|
| N0 | 1.85 (1.67) | -1.16 | 0.244 |
| N1 + N2 | 2.67 (0.79) |  |

Median serum B2M level was 2.50 (1.19) mg/l for patients with no distant metastasis (17 cases), and 2.67 (3.80) mg/l in patients positive for distant metastasis (4 cases); this, too, was not statistically significant (p=0.370) (Table 7).
Table 7: Comparison of serum B2M level according to distant metastasis, by the Mann-Whitney Test

| Distant metastasis | B2M level (mg/l) | Median (IQR) | z-statistic | p-value |
|--------------------|-----------------|--------------|-------------|---------|
| M0                 | 2.50 (1.19)     | -0.90        | 0.370       |
| M1                 | 2.67 (3.80)     |              |             |         |

Discussion

The age distribution among the 21 case group subjects showed most of them to be within the 60 to 69 age range, which is consistent with Malaysian oral cancer statistics. Malaysian statistics also show an almost equal gender incidence. However, gender distribution in the study sample revealed more male subjects within the case group (61.9%). This could be a reflection of the localized distribution seen in Kelantan.

The racial distribution of case subjects was mostly Malay, reflecting the racial composition of Kelantan state where Malays account for about 95% of the state population. Other minority races include those of immigrant Chinese and Indian descent [26].

Of the three most important risk factors associated with OSCC (smoking, betel quid chewing and alcohol consumption), smoking was found to be more prevalent in the case group (71.4%) as compared to betel quid chewing (23.8%) and alcohol consumption (0%). This is probably due to Malay Muslim religious beliefs that prohibit alcohol consumption among our predominantly Malay case subjects. Consistent with global data on common OSCC subsites, we found that the most common site of presentation of the primary tumour was the tongue (47.6%) followed by buccal mucosa (33.3%) [27].

All the OSCC patients presenting to us were in stage IV of the disease, and moderately differentiated squamous cell carcinoma (52.4%) was the most common histopathological presentation, followed by well-differentiated histology (47.6%), with no cases of poorly differentiated disease. While it is well established that patients with OSCC tend to present late, the overwhelming presence of stage IV cases in our study has not been previously reported. We posit that the status of HUSM as a tertiary referral centre, and a centre for oncological management in the East Coast of Peninsular Malaysia, to be the main reason for this unusual finding. Patients amenable to surgery would have been treated at their respective state hospitals. The local cultural preference for traditional and alternative therapy during the early stage of disease could be a further contributory factor.

Serum B2M level in the OSCC group was shown to have a statistically significant (p<0.001) increase, and is in line with findings of previous studies, although the mechanism of altered B2M level is not yet clearly understood [21,22,28,29]. Various postulates have been put forth, which include increased cellular activity, cell membrane turnover and cell division in malignancy [30]. Our study showed 90.5% sensitivity and 90.5% specificity by ROC analysis, consistent with other studies [23,31]. B2M was also found to have good diagnostic test accuracy measurements, with a Positive Likelihood Ratio of 9.53, Negative Likelihood Ratio of 0.10, Diagnostic Odds Ratio of 95.3 and a Youden Index value of 0.81. This is in agreement with a recent meta-analysis which concluded that B2M was one of four (prolactin, glutathione, and catalase) biomarkers with the highest diagnostic test accuracy [18].

Serum B2M levels were seen to correlate with a worsening degree of histological differentiation, although this was not statistically significant. This finding is incongruent with other studies; the possible reasons include a small sample size and the absence of poorly differentiated histology among our patient pool [32]. Median serum B2M levels were also not significantly increased for variables of nodal status and distant metastasis, unlike in tissue studies, where the association of B2M expression with progression and metastasis of OSCC lesions was statistically significant [24,25]. Other serum-based studies, however, did not analyse those variables [21-23,28,29,31], thus ruling out comparisons.

It is therefore apparent that B2M is a sensitive and specific serum tumour marker at a cut off value of 1.57mg/l to differentiate cases from controls, for a case group consisting of primarily Malay subjects. This can serve as an initial reference value for countries in the region with large Malay populations such as Malaysia and neighbouring Indonesia, since currently none exists.

The utility of B2M serum tumour marker as a singular screening tool is diminished because an elevated level has also been reported in cases of haematological malignancies, tumours of the breast, lung, and gastrointestinal and genitourinary tracts [29]. In addition, its role as a serum prognostic marker has yet to be verified conclusively in literature.
However, it can serve well as an adjunct diagnostic tool for the early diagnosis of OSCC, and to determine if a biopsy is warranted. Its utility lies in the fact that it is cost effective, minimally invasive, and yields results within a minimal timespan, as compared to more expensive alternatives such as oral brush biopsy. Furthermore, it avoids inter-observer variation associated with other protocols such as fluorescence spectroscopy and toluidine blue staining33. Most importantly, raised B2M levels served to increase the index of suspicion regarding the presence of OSCC, in the case of a negative biopsy.

**Conclusion**
The early diagnosis of oral squamous cell carcinoma (OSCC) is of paramount importance and the first step to achieving this is the further development of rapid, less invasive and accurate methods of screening and diagnosis. B2M holds great promise, when used as an adjunct with other recently developed techniques because of its low cost, minimally-invasive nature and quick availability of results.

**Limitations**
Our study has a few limitations: first, the sample size was small; second, our findings may have limited external validity due to its localisation to a single centre and were confined to a largely Malay sample. Finally, all of our patients presented an advanced stage of disease.

This research was fully funded by the Short Term Research Grant 304/PPSG/61313171 from Universiti Sains Malaysia.

**Conflict of Interest:** None declared.

**Authors’ contribution:**
Data gathering and idea owner of this study: Narayanan MS, NK Kassim, Liszen T, Abdullah B
Study design: Narayanan MS, NK Kassim, Abdullah B, Omar J, Hairon SM, Lazim NM
Data gathering: Narayanan MS, NK Kassim, Liszen T, Abdullah B, Omar J, Hairon SM
Writing and submitting manuscript: Narayanan MS, NK Kassim
Editing and approval of final draft: Narayanan MS, NK Kassim, Liszen T, Abdullah B, Omar J
References:

1. Webster K. Oral cavity tumour including the lip. In: Hibbert, J editor. Scott Brown’s Otorhinolaryngology, Head and Neck Surgery, 7th edition. Vol.2. London: Edward Arnold Publishers Ltd; 2008. 2543-76.

2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45:309-16.

3. Omar ZA, Ibrahim Tamin NS. National Cancer Registry Report 2007 Malaysia Cancer Statistics - Data and Figures. Malaysia: Ministry of Health Malaysia; 2008.

4. Pereira MC, Oliveira DT, Landman G, Kowalski LP. Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc. 2007; 73:339.

5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.

6. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Eng J Med 1993; 328:184–94.

7. Silverman S. Oral Cancer. Semin Dermatol 1994; 13:132–7.

8. Epstein JB, Güneri P, Boyacioglu H, Abt E. The limitations of the clinical oral examination in detecting dysplastic oral lesions and oral squamous cell carcinoma. J Am Dent Assoc. 2012; 143:1332-42.

9. Scully C, Bagan J, Hopper C. Oral cancer: current and future diagnostic techniques. Am J Dent. 2008; 21:200-8.

10. Seoane J, Varela-Centelles P, Ramirez JR, Romero MA, De La Cruz A. Artefacts produced by suture traction during incisional biopsy of oral lesions. Clin Otolaryngol. 2002; 27:549-53.

11. Mehrtra R, Gupta, DK. 2011. Exciting new advances in oral cancer diagnosis: avenues to early detection. Head Neck Oncol. 2011; 33:2-8.

12. EsmAILY HO. Oral cancer knowledge among patients referred to Mashhad Dental School, Iran. Arch Iran Med. 2010; 13:543.

13. Patton LL, Elter JR, Southerton JH, Strauss RP. Knowledge of oral cancer risk factors and diagnostic concepts among North Carolina dentists: implications for diagnosis and referral. J Am Dent Assoc. 2005; 136:576-8.

14. West R, Alkhatib MN, McNeill A, Bedi R. Awareness of mouth cancer in Great Britain. Br Dent J. 2006; 200:167-9.

15. Cai ZG, Shi XJ, Gao Y, Wei MJ, Wang CY, Yu GY. β-catenin expression pattern in primary oral squamous cell carcinoma. Chin Med J. 121:1866-70.

16. Berggård I, Bearn AG. Isolation and properties of a low molecular weight β2-globulin occurring in human biological fluids. J Biol Chem. 1968; 243:4095-103.

17. Child JA, Spati B, Illingworth S, Barnard, D, Corbett S, Simmons AV, et al. Serum beta 2- microglobulin and C-reactive protein in the monitoring of lymphomas. Cancer.1980;45:318-26.

18. Guerra EN, Rêgo DF, Elias ST, Coletta RD, Mezzomo LA, Gozal D, et al. Diagnostic accuracy of serum biomarkers for head and neck cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016; 101:93-118.

19. Kithier K, Cezja K, Belamaric J, Al-Sarrafl M, Peterson WO, Vaiktevicius VK, et al. β2-microglobulin: occurrence in fetal life and malignancy. Clin Chim Acta. 1974; 52:293-9.

20. Saddiwal R, Hebbale M, Sane V, Hiremurt D, Gupta R, Merchant Y. Estimation of serum beta 2-microglobulin levels in individuals exposed to carcinogens: clinical study in Indian population. J Maxillofac Oral Surg. 2016;16(1):53-57.

21. Vaishali N, Tukpali JV. An estimation of serum β-2 microglobulin level in premalignant lesions / conditions and oral squamous cell carcinoma: a clinicopathological study. J Oral Maxillofac Pathol. 2005; 9:16-19.

22. Silvia CW, Vasudevan DM, Prabhu KS. Alteration of serum β2-microglobulin in oral carcinoma. Ind J Clin Biochem. 2002; 17:104-7.

23. Rasool M, Khan SR, Malik A, Khan KM, Zahid S, Manan A, et al. Comparative studies of salivary and blood sialic acid, lipid peroxidation and antioxidative status in oral squamous cell carcinoma (OSCC). Pak J Med Sci. 2014; 3:466-71.

24. Jiang Q, Patima S, Ye DX, Pan HY, Zhang P, Zhang ZY. Upregulation of β2-microglobulin expression in progressive human oral squamous cell carcinoma. Oncol Rep. 2012; 27:1058-64.

25. Chen CH, Su CY, Chien CY, Huang CC, Chuang HC, Fang FM, et al. Overexpression of β2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J of Cancer. 2008; 99:1453-61.

26. Sathian MR, Yeok MN. Essentialising ethnic and state identities: strategic adaptations of ethnic Chinese in Kelantan, Malaysia. Asian Studies Review. 2014; 38:385-402. doi:10.1080/10357823.2014.936361.

27. Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017; 67:51-64.

28. Manzar W, Raghavan MR, Aroor AR, Keshavamurthy KR. Evaluation of serum β2- microglobulin in oral cancer. Aust Dent J. 1992; 37:39-42.

29. Anil S, Beena VT, Nair RG, Vijayakumar T. Evaluation of serum beta 2-microglobulin in premalignant and malignant lesions of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 79:750–2.

30. Vinzenz K, Schönthal E, Zekert F, Wunderer S. Diagnosis of head and neck carcinomas by means of immunological tumour markers (Beta-2-microglobulin, immunoglobulin E, ferritin, N-acetyl-neuraminic acid, phosphohexose-isomerase). J Craniomaxillofac Surg. 1987; 15:270-7.

31. Singh AP, Kumar N, Raju MS, Singh NN, Nagendrareddy SG. Estimation of serum β2-microglobulin in potentially malignant disorders and squamous cell carcinoma of oral cavity: a clinicopathologic study. Dent Res J. 2014; 11:109-13.

32. Diwan NN, Chavan MS, Motgi AA, et al. Evaluation of serum beta-2 microglobulin as a diagnostic and prognostic marker in oral squamous cell carcinoma and leukoplakia. Arch Can Res. 2016; 4: 4.

33. Carreras-Torras C, Gay-Escoda C. Techniques for early diagnosis of oral squamous cell carcinoma: Systematic review. Med Oral Patol Oral Cir BucaI. 2015; 20; e305-e315. doi:10.4317/medoral.20347.